Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 20, 2021 09:00 ET | Source: COMPASS Pathways

Open-label study of COMP360 psilocybin therapy for depression in cancer patients demonstrates feasibility of simultaneous psilocybin administration in small groups

Investigator-initiated study shows remission in major depression symptoms for 50% of participants London, UK – 20 October 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health...